Passionate about IP! Since June 2003 the IPKat has covered copyright, patent, trade mark, designs, info-tech and confidentiality issues from a mainly UK and European perspective. Read, post comments and participate!

The team is Eleonora Rosati, Annsley Merelle Ward and Merpel. E-mail the Kats here!

The team is joined by GuestKats Söğüt Atilla, Oliver Fairhurst, Claire Gregg, Georgia Jenkins and Marcel Pemsel.

SpecialKats: Verónica Rodríguez Arguijo (TechieKat), Rose Hughes (PatKat) and Jocelyn Bosse (Book Review Editor).

InternKats: Wissam Bentazar, Simone Lorenzi and Kliment Markov.
Results for PatKat
Reform, resist, or rethink: Responses from CIPA, the PEB and the Paralegal Committee to IPReg's Education Review Reform, resist, or rethink: Responses from CIPA, the PEB and the Paralegal Committee to IPReg's Education Review Reviewed by Dr Rose Hughes on Sunday, July 05, 2026 Rating: 5
[GuestPost] Through the Examiner’s Lens: Understanding the New EQE Format [GuestPost] Through the Examiner’s Lens: Understanding the New EQE Format Reviewed by Dr Rose Hughes on Friday, July 03, 2026 Rating: 5
When do you file for a drug combination invention? (T592/24) When do you file for a drug combination invention? (T592/24) Reviewed by Dr Rose Hughes on Monday, June 22, 2026 Rating: 5
AI in the patent industry: Bubble trouble and the affordability myth AI in the patent industry: Bubble trouble and the affordability myth Reviewed by Dr Rose Hughes on Tuesday, June 16, 2026 Rating: 5
New referral on claim interpretation and relevance of G1/24 to added matter confirmed (G1/26) New referral on claim interpretation and relevance of G1/24 to added matter confirmed (G1/26) Reviewed by Dr Rose Hughes on Thursday, June 04, 2026 Rating: 5
AI in the patent industry: The risks of AI shadow use AI in the patent industry: The risks of AI shadow use Reviewed by Dr Rose Hughes on Monday, May 18, 2026 Rating: 5
Be careful what you wish for: Method of treatment claim for an antibody genus found to satisfy both written description and enablement requirement (Teva v Eli Lilly) Be careful what you wish for: Method of treatment claim for an antibody genus found to satisfy both written description and enablement requirement (Teva v Eli Lilly) Reviewed by Dr Rose Hughes on Monday, May 18, 2026 Rating: 5
Subscribe to: Posts ( Atom )
Powered by Blogger.